Erythema immunoglobulin

Skin reactions to intravenous immunoglobulin are rare (52,93-95). Other reported reactions include urticaria, maculopapular rashes, petechiae, eczema, and erythema multiforme (31,96). 

Dapsone is approved for use in dermatitis herpetiformis and leprosy. It is particularly useful in the treatment of linear immunoglobulin A (IgA) dermatosis, bullous systemic lupus erythematosus, erythema elevatum diutinum, and subcorneal pustular dermatosis. 

Skin Cutaneous reactions that are associated with intravenous immunoglobulin include erythema at the injection site, rashes, urticaria [40 ], and eczema [43 ]. 

The most commonly reported adverse events are mild local injection reactions, such as erythema, edema, swelling, pruritus, and local heat [48 , 60, 63 ], whose incidence decreases over time [48 ]. The incidence of non-infusion-site reactions after subcutaneous administration (0.24 events per infusion) is similar to the total incidence of 0.25 events per infusion during treatment with intravenous immunoglobulin [48 ]. Non-infusion-site adverse events after subcutaneous administration include headache, diarrhea, fatigue, and nausea [48 "]. 

Skin Cutaneous reactions associated with intravenous immunoglobulin are uncommon, but include pruritus, non-specific eruptions, erythema, urticaria, eczema, pompholyx, pete-chiae, and skin hemorrhage [53, 54 , 55 , 57 , 59 ]. 

---